<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00730418</url>
  </required_header>
  <id_info>
    <org_study_id>2006-08-118</org_study_id>
    <nct_id>NCT00730418</nct_id>
  </id_info>
  <brief_title>Effects of Chronic Use of Doxazosin in Men With Benign Prostatic Hyperplasia</brief_title>
  <official_title>A Prospective Study for the Effects of Chronic Use of Doxazosin on Alpha 1-adrenergic Receptors in Men With Benign Prostatic Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, we investigate the changes of the expression of alpha adrenergic receptor in
      the prostate tissue during 2-yr medication period in the man with benign prostatic
      hyperplasia. And we also evaluate the efficacy and safety of 24 mo-treatment with doxazosin
      (4mg, 8mg)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the expression of alpha-1 adrenergic receptors, we will use various methodologies
      such as

        -  Real-time RT-PCR

        -  Radioligand receptor binding

        -  Western blot

        -  Immunohistochemistry
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Expression of alpha-1 adrenoceptor</measure>
    <time_frame>before treatment and 12mos and 24 mos after treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>International Prostate Symptom Score, Patient perception of bladder condition, Maximal flow rate of urine, Postvoid Residual, Prostate volume, Serum PSA level, Adverse events</measure>
    <time_frame>before treatment and 3mos, 12mos, and 24mos after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>doxazosin 4mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>doxazosin 4mg group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>doxazosin 8mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>doxazosin 8mg group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxazosin</intervention_name>
    <description>Treatment with doxazosin 4mg daily for 24 mos</description>
    <arm_group_label>doxazosin 4mg</arm_group_label>
    <other_name>Cadura XL 4mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxazosin</intervention_name>
    <description>Treatment with doxazosin 8mg daily for 24 mos</description>
    <arm_group_label>doxazosin 8mg</arm_group_label>
    <other_name>Cadura XL 8mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  50 yrs or greater

          -  International prostatic symptom score &gt;= 8

          -  Maximal flow rate &lt; 15mL/sec

          -  baseline PSA 2.5-10 ng/mL

          -  Pathologically proven BPH

          -  No medication history for BPH

          -  Able to give fully informed consent

        Exclusion Criteria:

          -  Previous use of alpha-blocker, 5-alpha reductase inhibitor

          -  Previous surgery for BPH

          -  Urologic cancer history

          -  Urethral stricture

          -  baseline PSA &gt; 10ng/mL

          -  BP &lt; 90/70 mmHg

          -  Orthotopic hypotension with syncope

          -  Serum Cr &gt; 2.0 mg/dl, alanine aminotransferase &gt; 1.5 times of normal limit

          -  Bacterial prostatitis within 1 year

          -  Urinary tract infection(UTI) more than 2 times within 1 year

          -  Active UTI or prostate biopsy within 1 month

          -  Unable to void

          -  Ped use because of incontinence

          -  Hypersensitivity to alpha-blocker that include quinazoline

          -  Unstable angina, Myocardial infarction, or cerebrovascular accident within 6 months

          -  Neurogenic bladder dysfunction (ex. multiple sclerosis, Parkinson's disease, Spinal
             injury etc.)

          -  Psychiatric problem

          -  Alcohol abuse or other drug abuse history

          -  Severe comorbidities unable to perform long-term trial

          -  seems not to be appropriate to this study because of any other reasons
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kru-Sung Lee, Ph.D., M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>SEoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 7, 2008</study_first_submitted>
  <study_first_submitted_qc>August 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2008</study_first_posted>
  <last_update_submitted>August 25, 2010</last_update_submitted>
  <last_update_submitted_qc>August 25, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2010</last_update_posted>
  <responsible_party>
    <name_title>Kyu-Sung Lee/Professor</name_title>
    <organization>Samsung Medical Center</organization>
  </responsible_party>
  <keyword>Benign Prostatic Hyperplasia</keyword>
  <keyword>alpha Adrenergic Blockers</keyword>
  <keyword>alpha-1 Adrenergic Receptor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenergic Agents</mesh_term>
    <mesh_term>Doxazosin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

